Gujarat Themis Biosyn's Q1 FY 2026-27 Quarterly Results

Result Summary

• Gujarat Themis Biosyn Ltd reported a - quarter-on-quarter (QoQ) - in its consolidated revenues for the quarter-ended Jun (Q1 FY 2026-27). On a year-on-year (YoY) basis, it witnessed a - of -.
• Its expenses for the quarter were - by - QoQ and - - YoY.
• The net profit - - QoQ and - - YoY.
• The earnings per share (EPS) of Gujarat Themis Biosyn Ltd stood at 1.02 during Q1 FY 2026-27.

Financial Statments for Q1 FY 2026-27

---

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Gujarat Themis Biosyn Ltd is a pharmaceutical company based in India, primarily engaged in the production of bulk drugs and active pharmaceutical ingredients (APIs). The company operates within the pharmaceutical industry, focusing on the synthesis and manufacturing of high-quality chemical compounds used in the production of various medications. Although specific recent developments or product launches for Gujarat Themis Biosyn Ltd are not available within the provided data, the company has historically been involved in collaborations and partnerships to enhance its manufacturing capabilities and product offerings.

Revenue

In Q1FY27, Gujarat Themis Biosyn Ltd reported a total income of ₹43.92 crores. This figure represents the company's total revenue generated during the first quarter of fiscal year 2027. Due to the absence of comparative data from the previous quarter, Q4FY26, and the corresponding quarter of the previous fiscal year, Q1FY26, it is not possible to calculate the quarter-over-quarter (QoQ) or year-over-year (YoY) changes in revenue. The financial data provided does not include previous period figures, which limits the analysis to the current quarter's performance only.

Profitability

For Q1FY27, Gujarat Themis Biosyn Ltd recorded a profit before tax of ₹15.17 crores and a profit after tax of ₹11.07 crores. With a recorded tax expense of ₹4.10 crores, the company has demonstrated its ability to maintain profitability in its operations. The earnings per share (EPS) for the quarter stood at ₹1.02. As there is no available data for Q4FY26 or Q1FY26, it is not possible to ascertain the quarter-over-quarter or year-over-year changes in profitability metrics. The absence of this historical data limits the analysis to the current quarter's figures.

Operating Metrics

The operating expenses for Gujarat Themis Biosyn Ltd in Q1FY27 amounted to ₹28.76 crores. This figure represents the total costs incurred by the company in its operations during the quarter. The financial data lacks comparative figures from previous quarters, which prevents the calculation of specific trends or anomalies in operating expenses over time. Without historical data, it is not feasible to determine the efficiency of the company's operational management relative to past performance. The current data provides a snapshot of operating expenses without a comparative baseline.